Патоморфологічні зміни у щурів при експериментальній моделі хронічного вірусного гепатиту

Автор(и)

  • О. P. Shevchenko ДЗ «Дніпропетровська медична академія МОЗ України», Україна

DOI:

https://doi.org/10.26641/1997-9665.2015.3.111-116

Ключові слова:

хронічний гепатит, патогенетичне лікування, L-аргініну L-глутамат, Цитофлавін

Анотація

Вивчались патоморфологічні зміни печінки у щурів при експериментальній моделі хронічного вірусного гепатиту на тлі застосування патогенетичних препаратів, L-аргинина L-глутамату - гепатопротектору Глутаргін і комбінованого метаболічного засобу Цитофлавін; вивчався їх вплив на процеси фіброгенезу в печінці. З’ясовано, що найбільшу ефективність мав L-аргініну L-глутамат, спостерігалось більше уповільнення фібротичних процесів, що обґрунтовує доцільність застосування препаратів в комплексному лікуванні хворих на хронічний гепатит.

Посилання

EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2015;63:199-236. At: http://www. easl.eu/medias/cpg/HEPC-2015/Full-report.pdf.

Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis. 2001;21:437-51. PMID: 11586471.

Serov VV, Shehter AB. [Connective tissue (functional morphology and general pathology)] Moscow: Meditsina; 1981. 312 p. Russian.

Fedorchenko SV. [Chronic HCV-infection: monograph]. Kyiv: Medytsyna; 2010. 272 p. Ukrainian.

Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology. 2000;32(6):1403-8. PMID: 11093750.

Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99(6):1160-74. PMID: 15180741.

Malyi VP, Zvyaginceva TD, Titovskii SP. [HCV infection (acute and chronic): clinical, pathogenetic and therapeutic aspects]. Kyiv; 2005. 292 p. Russian.

Sherlock S, Duli G, authors. [Diseases of the liver and biliary tract] [translated from English]. Moscow: GEOTAR-Meditsina; 2002. 864 p. Russian.

Desmet VJ. Histological classification of chronic hepatitis. Acta Gastroenterol Belgica. 1997;60(4):259-67.

Shevchenko OP, Suremenko MS, Svyatenko TV, Bіla-Popovich GS, Striga VA. [Infection with viral hepatitis B and C among patients with different pathologies in risk groups and the general population in the Dnipropetrovsk region]. Dermatovenerologiya, Kosmetologiya, Seksopatologiya. 2007;(1-4):144-8. Ukrainian.

Andreichin MA., Drizhak VІ, Ryabokon OV, Kopcha VS. [Viral hepatitis and liver cancer] Ternopіl: TDMU; 2010. 188 p. Ukrainian.

Pavlov ChS. [The principles of diagnosis and treatment approaches to fibrosis and cirrhosis of liter]. Ross Med Zh. 2007;9(1):11-5. Russian.

Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 2002 May;122(5):1525-8.. PMID: 11984538.

Kobrin TІ, Telegіn DE. [Predicting effectiveness of antiviral therapy in patients with chronic hepatitis C]. Іnfektsіinі hvoroby. 2010;(2):69-79. Ukrainian.

Pawlotsky JM. Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology. 2015 Mar;148(3):468-79. doi: 10.1053/j.gastro.2015.01.002. PMID: 25576860.

Serpaggi J, Carnot F, Nalpas B, Canioni D, Guéchot J, Lebray P, Vallet-Pichard A, Fontaine H, Bedossa P, Pol S. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol. 2006 Dec;37(12):1519-26. PMID: 16997354.

Brenner DA. Reversibility of Liver Fibrosis. Gastroenterol Hepatol. 2013;9(11):737-9. PMCID: PMC3995196.

Shevchenko OP, Pokrova OD, Bіla-Popovich GS. [Treatment of viral hepatitis on a background of uremia]. Dermatovenerologiya, Kosmetologiya, Seksopatologiya. 2006;(3-4):174-7. Ukrainian.

Fadeenko GD, Kushnir IE', Chernova VM, Solomenceva TA [et al.]. [Application of glutargin of patients with liver cirrhosis]. In: [Collected works of scientific-practic. conf. "Glutargіn - new principles of pharmacotherapy of liver disease"; 2003; Kharkіv, Ukraine]. Kharkіv; 2003. p.58-9.

Gubergric NB. [Chronic hepatitis and cirrhosis of the liver. Modern classification, dіagnostics and treatment: a training manual]. 3rd ed., rev. and enl. Kyiv: ZAO Vіpol; 2010. 328 p. Russian.

Matyash VI. [Evaluation of the effectiveness glutargin in Integrated viral therapy hepatitis]. In: [Application of the new Ukrainian Glutargin drug in clinical practice: A guide for practitioners; 2003; Kharkiv and Lugansk, Ukraine]. Kharkiv, Lugansk; 2003. p. 44-50. Russian.

Golubovska OA, editor. [Infectious diseases: textbook]. Kyiv: Medytsyna; 2012. 728 p. Ukrainian.

Shostakovich-Koretska LR, Andreeva IA, Shevchenko OP. [Cabinet of infectious diseases: the structure, functions and organization of work: study guide]. Dnepropetrovsk; 2013. 175 p. Ukrainian.

Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology. 2000 Aug;32(2):247-55. PMID: 10915731.

Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology. 2001;34(2):288-297. PMID: 11481614.

Shevchenko OP, Fomenko OZ, Shevcova AІ, Ushakova GO. [Changes of matrix metalloproteinase activity and glycosaminoglycans in conditions of chronic hepatitis induced in rats]. Odessa medical journal. 2009;(6):31-3. Ukrainian.

Babak OYa. [Application of the new drug glutargin in gastroenterology]. Suchasna gastroenterologіya. 2003;2(12):85-9. Russian.

Baranova IP, Zykova OA, Konnova OA. [Viral hepatitis A: cytoflavin metabolic therapy: A guide for doctors]. Penza; 2006. 18 p. Russian.

Shevchenko OP, Suremenko MS, Bіla-Popovich GS. [Glutargin efficacy in treatment of patients with cirrhosis]. Naukovyi vіsnyk Uzhgorodskogo universytetu. Serіes: Medicine. 2009;36:35-7. Ukrainian.

Sukhanov DS. [Application of cytoflavin therapy for medicinal liver lesions in patients with pulmonary tuberculosis] In: [Proceedings of XIII Russian National Congress "Human and medicine"; 2006; Moscow, Russia]. Moscow; 2006. p. 297. Russian.

Nіkolenko VYu, Nіkolenko YuІ, Nіkolenko OYu; inventors; Horkyi Donetsk State Medical University, assignee. Method for simulating chronic hepatitis type "C". Ukrainian patent UA 15752. 2006 Jul 17. Int Cl. G09B 23/28. Ukrainian.

Shevchenko OP. [Study of glutargin antyfibrotyc action in experimental models of chronic hepatitis C] In: [Liver disease in clinical practice: materials scientific-practic. conf. with intern. participation; 2009; Kharkіv, Ukraine]. Kharkіv; 2009. p.191-2. Ukrainian.

Shevchenko OP, Fomenko OZ. [The cytoflavin impact on liver regeneration and contents of the extracellular matrix in experimental hepatitis in rats]. In: [Current issues of pharmaceutical and medical science and practice 2011: All-Ukrainian scientific-practic. conf. with Intern. participation ‘Modern aspects of medicine and pharmacy-2011’; Zaporizhzhia, Ukraine]. Zaporіzhzhya; 2011. Vol. 24, part 2. p. 18. Ukrainian.

##submission.downloads##

Номер

Розділ

Статті